RGD Reference Report - Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus.

Authors: Bogdanski, P  Pupek-Musialik, D  Dytfeld, J  Jagodzinski, PP  Jablecka, A  Kujawa, A  Musialik, K 
Citation: Bogdanski P, etal., Int J Clin Pharmacol Ther. 2007 Oct;45(10):563-7.
RGD ID: 2307064
Pubmed: PMID:17966842   (View Abstract at PubMed)

OBJECTIVE: Leukocyte migration to the subendothelial space is considered crucial in the initiation of atherosclerosis. There is increasing evidence that overexpression of chemokine receptors contribute to this process. CCR5 is one of the receptors present on peripheral T lymphocytes, monocytes and macrophages. We decided to evaluate the expression of CCR5 on monocytes and macrophages in peripheral blood and selected inflammatory markers in patients with type 2 diabetes mellitus before and after the initiation of insulin therapy. MATERIAL AND METHODS: A total of 10 patients with newly diagnosed type 2 diabetes and 6 healthy control subjects were studied. Assessment of CCR5 expression on the surface of monocytes and macrophages in peripheral blood was performed using flow cytometry before the initiation of insulin therapy and after 5-week treatment. Serum concentrations of RANTES, TNF-alpha, IL-6 and hsCRP were assessed. RESULTS: When compared to control subjects, we observed higher densities of CCR5 on the surface of peripheral blood monocytes and macrophages and higher concentrations of RANTES, TNF-alpha, IL-6 and hsCRP before insulin therapy. After 5-week insulin therapy, there was a significant decrease in the expression of CCR5 on the surface of these cells and a significant fall in serum levels of RANTES, IL-6, TNF-alpha and hsCRP. CONCLUSIONS: Type 2 diabetes leads to an increase in the inflammatory process, and insulin therapy inhibits the early stages of this process.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
type 2 diabetes mellitus  IEP 2307064protein:increased expression:serumRGD 
type 2 diabetes mellitus  IEP 2307064protein:increased expression:monocyteRGD 
type 2 diabetes mellitus  ISOCCL5 (Homo sapiens)2307064; 2307064protein:increased expression:serumRGD 
type 2 diabetes mellitus  ISOCCR5 (Homo sapiens)2307064; 2307064protein:increased expression:monocyteRGD 

Objects Annotated

Genes (Rattus norvegicus)
Ccl5  (C-C motif chemokine ligand 5)
Ccr5  (C-C motif chemokine receptor 5)

Genes (Mus musculus)
Ccl5  (C-C motif chemokine ligand 5)
Ccr5  (C-C motif chemokine receptor 5)

Genes (Homo sapiens)
CCL5  (C-C motif chemokine ligand 5)
CCR5  (C-C motif chemokine receptor 5)


Additional Information